In the context of cancer immunotherapy, CXCL10 enhanced dendritic cell-antigen presentation and subsequent tumor cell killing by T cells in the presence of tumor vaccines in melanoma50,51 and glioma models52,53. This evidence concerns the gene CXCL10 and central nervous system cancer.